Shares of Lixte Biotechnology Holdings Inc. (LIXT) are surging over 55% on Friday morning despite no stock-related news to drive the shares.
LIXT is currently trading at $5.88, up $2.11 or 55.97%, on the Nasdaq.
Lixte Biotechnology operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets.
The company's flagship product is LB-100, which the company believes has serious potential as an anti-cancer agent, whether used alone or in combination with other therapies.
For comments and feedback contact: editorial@rttnews.com
Business News